510(k) device
Espin System
Nlt Spine, Ltd. · Arthroscope (HRX, Class II) · First FDA decision Aug 9, 2012, newest Nov 27, 2013Ligament, tendon and cartilage injuries
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
1
Naming "Espin"
MAUDE reports
0
Brand "Espin", since 2015
PubMed studies
132
Mentioning "Espin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Espin System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- ESPIN SYSTEM510(k)
K133061 · Decided Nov 27, 2013 · 61 days after receipt
Device type: Arthroscope (HRX) · Orthopedic Surgery
- ESPIN510(k)
K130057 · Decided Feb 7, 2013 · 29 days after receipt
Device type: Arthroscope (HRX) · Orthopedic Surgery
- ESPIN510(k)
K120553 · Decided Aug 9, 2012 · 168 days after receipt
Device type: Arthroscope (HRX) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Espin", any status and sponsor, newest update first.
NLT SpineNot on our public-company list
NCT01850537 · 15 participants (planned) · Start May 2013 · Primary completion Dec 2016
Device: treatment of degenerative disc disease using the PROW LIF · For: Degenerative Disc Disease
Sites: Kfar Saba, Israel
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Espin", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HRX
18,629 reports: 17,308 malfunction, 1,310 injury, 2 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Espin"[tiab]. The summary above synthesizes these.
- Espin enhances confined cell migration by promoting filopodia formation and contributes to cancer metastasis.
Wang Y, Shi P, Liu G, et al. · EMBO Rep · 2025
- Espin cross-links cause the elongation of microvillus-type parallel actin bundles in vivo.
Loomis PA, Zheng L, Sekerková G, et al. · J Cell Biol · 2003Research Support, U.S. Gov't, P.H.S.
- Espin distribution as revealed by super-resolution microscopy of stereocilia.
Qi J, Zhang L, Tan F, et al. · Am J Transl Res · 2020
- Espin overexpression causes stereocilia defects and provides an anti-capping effect on actin polymerization.
Zheng L, Adam SA, García-Anoveros J, et al. · Cytoskeleton (Hoboken) · 2022Research Support, N.I.H., Extramural
- The role of Espin in the stereocilia regeneration and protection in Atoh1-overexpressed cochlear epithelium.
Yang X, Qi J, Zhang L, et al. · Cell Prolif · 2023
- Espin cytoskeletal proteins in the sensory cells of rodent taste buds.
Sekerková G, Freeman D, Mugnaini E, et al. · J Neurocytol · 2005Research Support, N.I.H., Extramural
- Actin Bundles Dynamics and Architecture.
Rajan S, Kudryashov DS, Reisler E · Biomolecules · 2023Review, Research Support, N.I.H., Extramural
- Studies of functional properties of espin 1: Its interaction to actin filaments.
Yang JB, Kim KS, Heo J, et al. · Front Cell Dev Biol · 2022
- Espin contains an additional actin-binding site in its N terminus and is a major actin-bundling protein of the Sertoli cell-spermatid ectoplasmic specialization junctional plaque.
Chen B, Li A, Wang D, et al. · Mol Biol Cell · 1999Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Espin gene (ESPN) mutations associated with autosomal dominant hearing loss cause defects in microvillar elongation or organisation.
Donaudy F, Zheng L, Ficarella R, et al. · J Med Genet · 2006Letter, Research Support, N.I.H., Extramural
- Actin-binding protein, Espin: a novel metastatic regulator for melanoma.
Yanagishita T, Yajima I, Kumasaka M, et al. · Mol Cancer Res · 2014Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code HRX.
- SmartRelease Endoscopic Soft Tissue Release SystemMicroaire Surgical Instruments · 510(k) 2023
- Spinevu Endoscopic Spine System (Sess)Spine View, Inc. · 510(k) 2012
- Endius Atavi SystemEndius, Inc. · 510(k) 2006
- Sky Bone Expander System (Sky System)Disc-O-Tech Medical Technologies, Ltd. · 510(k) 2004
- Digital ClarusScope System and Digital NeuroPEN SystemClarus Medical, LLC · 510(k) 2026
- Arthrex Spine EndoscopeArthrex, Inc. · 510(k) 2025
- CORUS Spinal System-XProvidence Medical Technology, Inc. · 510(k) 2021
- Voyant SystemViseon, Inc. · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.